Copyright Reuters
LONDON, Nov 5 (Reuters) - Novo Nordisk said on Wednesday it has accepted the U.S. Inflation Reduction Act (IRA)'s maximum fair price for its diabetes and obesity medicines Ozempic, Wegovy and Rybelsus, which will become effective in January 2027. Novo made the disclosure in its quarterly earnings report. Sign up here. The price negotiation process was established under President Biden's signature IRA in 2022. Novo's drugs are among 15 selected as the second group of medications undergoing the process, and are among the most expensive for the Medicare health program for people aged 65 and older or with disabilities. Reporting by Maggie Fick; Editing by Jan Harvey
